Page 21 - Jack Bailey News Today

Several of these recommended books on the Chisholm Trail are available for free online. Writers and readers can’t get enough stories about those 1800s cattle trails. As you read this, I am out of the office. Yet I did not forget the statewide readership of the Think, Texas newsletter and column. In my absence, allow me to offer an Aug. 20, 2017, column about the Chisholm Trail written by my colleague Glen Seeber of the Oklahoman, a sibling Gannett newspaper in the USA Today Network. While the...

February 17, 2021 7:38 PMGayVN - By SAN FRANCISCO—NakedSword Originals has released the first episode of its second feature of 2021, Lake Need, starring popular gay performer Johnny Rapid. In this episode, Rapid rounds up all his best buds and heads to Lake Need for a boy’s trip, but beyond the serene waters, theres nonstop bareback action on deck in this sun-drenched adventure now playing only on NakedSword.com. Director Edward James is the captain of a houseboat on Lake Need thats popu...

by Barry Teater, NCBiotech writer — February 16, 2021 . RESEARCH TRIANGLE PARK – After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung can...

The FDA approved G1s Cosela on Friday. (FDA) Despite the ever-growing use of targeted oncology drugs, chemotherapy is still widely used in lung cancer—and it still comes with potentially severe side effects. G1 Therapeutics just won FDA approval for a therapy that can help combat one of the most serious. G1s Cosela scored a green light to reduce the bone marrow damage that can come along with chemo. Given ahead of certain chemotherapy regimens to patients with extensive-stage small-cell ...

  After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).  “Cosela will help change the chemotherapy experience for people w...

Several of these recommended books on the Chisholm Trail are available for free online. Writers and readers can’t get enough stories about those 1800s cattle trails. As you read this, I am out of the office. Yet I did not forget the statewide readership of the Think, Texas newsletter and column. In my absence, allow me to offer an Aug. 20, 2017, column about the Chisholm Trail written by my colleague Glen Seeber of the Oklahoman, a sibling Gannett newspaper in the USA Today Network. While the...

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression February 12, 2021 19:41 ET | Source: G1 Therapeutics G1 Therapeutics - COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulte...

Radio was important to me when I was growing up.

Now that 2020 is basically a known quantity, Equipment World editors reached back to several of the contractors we talked with this spring with one basic question: what happened? We learned that 2020 was far from a universal experience. Read on. Rick Goodmanson Roseville, Minnesota “It was a wild ride, that’s for sure,” Rick Goodmanson says. “This year has been the most difficult of my career – No. 1, No. 2 and No. 3, probably all together.” In March, the commercial concrete and as...

particular order, a link to the place or it might be the burglar was acting on the instructions of the press to gain sight of inside of your flight, but we dont know which -- >> or both. i think the most likely scenario is both. >> or a burglar -- decided here somewhere he can make some money. >> whatever. fine. but they were very, this was at a time when there a lot of press outside all the time, desperate to get them. it was in the ...